Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. - Wikidata - wikimedia - TriplyDB

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

http://www.wikidata.org/entity/Q37524930

about

Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting.Targeting non-Hodgkin lymphoma with blinatumomab.Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia.

P2860

Q38287476-E0206EAC-3203-44DB-9F8D-E783AA9EA64C Q38770594-54B03556-9CB8-4D90-AE87-4AFF2B561896 Q53758334-E8CF1B3A-1136-4C0C-995B-496B856F776A

P2860

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

http://www.wikidata.org/entity/Q37524930

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 December 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

@en

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

@nl

type

label

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

@en

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

@nl

prefLabel

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

@en

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

@nl

P1433

Q37524930-4420BFFD-80AD-4E09-9B37-5B756A0B9DC7

P1476

Q37524930-A8D29981-9BF9-4645-A251-4214F9D8B5F0

P2093

Q37524930-19764549-F4E7-4D6F-994D-289220DA3AEF

Q37524930-242555AA-6841-41BF-BBED-1F6D08CA08DE

Q37524930-58D9BE57-CF5D-4416-BAEE-6E4DD1FE4BDD

Q37524930-68903572-C73B-485F-94C1-7F253AC56D97

Q37524930-D18DB69C-22CC-446D-A2E0-D85334FB9CD4

Q37524930-F3876ACF-A133-4E9E-9605-D9C1FA834201

P2860

Q37524930-0927FB93-9537-46DC-9A50-3B07C501B54B

Q37524930-104049A4-9EA3-4BD6-BBED-2395E89303BC

Q37524930-314C4028-F2DB-45F9-8201-8364306A2BCB

Q37524930-39F30661-004C-4AAC-8501-8FCB872120AD

Q37524930-3B36769E-D9BA-4546-ABAF-6C5D5104C40C

Q37524930-3F323D1F-F318-45E4-984E-FC10C14A261D

Q37524930-42D5EBF5-5648-444A-A8E9-F70ED6CC26CC

Q37524930-4793C371-E4E7-4681-B214-04DEF049DA56

Q37524930-56CDC96F-2B54-49E9-83AD-B2932DACB854

Q37524930-65DB6077-CE84-4C7D-A84B-B829084D63E5

P304

Q37524930-287314A0-27DE-44A6-84FD-8C90859BE379

P31

Q37524930-80CA19BA-A5D3-4C74-B22E-CC3F040DBE07

P356

Q37524930-88A450F8-23D6-4A38-8216-9ED46F63B9D1

P433

Q37524930-3A314B3D-CD26-43BF-B5B1-27C3A4F06156

P478

Q37524930-184AD022-D912-4808-AD4F-4D73E7DC8C34

P577

Q37524930-46A0451F-B8BB-4AE7-86A5-1489CCA11B7B

P698

Q37524930-ADD6BFAA-8A39-417E-82D3-11B83009232A

P932

Q37524930-878D4A11-ACA6-428F-A710-C6E6CBD046DD

P356

P1433

Current Oncology

P1476

Emerging therapies for the treatment of relapsed or refractory follicular lymphoma.

@en

P2093

A Christofides

http://www.w3.org/2001/XMLSchema#string

A Prica

http://www.w3.org/2001/XMLSchema#string

D MacDonald

http://www.w3.org/2001/XMLSchema#string

L H Sehn

http://www.w3.org/2001/XMLSchema#string

S Assouline

http://www.w3.org/2001/XMLSchema#string

T Lawrence

http://www.w3.org/2001/XMLSchema#string

P2860

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma.

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.

Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study.

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study.

Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

P304

407-417

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.23.3405

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P577

2016-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28050137

http://www.w3.org/2001/XMLSchema#string

P932

5176374

http://www.w3.org/2001/XMLSchema#string